Novoprotein Scientific Valuation

Q: What is the Fair Price of 688137 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

688137 (CN¥34.62) is trading above our estimate of [[fair value]] (CN¥1.16)

Is 688137 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 688137 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 688137 (CN¥34.62) is trading above our estimate of fair value (CN¥1.16)

Significantly Below Fair Value: 688137 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 688137?

Key metric: As 688137 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for 688137. This is calculated by dividing 688137's market cap by their current revenue.
What is 688137's PS Ratio?
PS Ratio	18x
Sales	CN¥134.56m
Market Cap	CN¥2.41b

688137 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	13.5x
Enterprise Value/EBITDA	-26.2x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does 688137's PS Ratio compare to its peers?

The above table shows the PS ratio for 688137 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	10x
688426 Jiangsu CoWin Biotech	20.2x	n/a	CN¥2.3b
300381 Guangdong VTR Bio-Tech	4.5x	n/a	CN¥3.5b
300485 Beijing Science Sun Pharmaceutical	9.3x	n/a	CN¥3.7b
688767 Hangzhou Biotest BiotechLtd	6.2x	n/a	CN¥3.2b
688137 Novoprotein Scientific	18x	n/a	CN¥2.4b

Price-To-Sales vs Peers: 688137 is expensive based on its Price-To-Sales Ratio (18x) compared to the peer average (10x).

Price to Sales Ratio vs Industry

How does 688137's PS Ratio compare vs other companies in the CN Biotechs Industry?

1 Company	Price / Sales	Estimated Growth	Market Cap
603716 Thalys Medical Technology Group	0.9x	n/a	US$211.94m

No more companies available in this PS range

1 Company		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: 688137 is expensive based on its Price-To-Sales Ratio (18x) compared to the CN Biotechs industry average (7.5x).

Price to Sales Ratio vs Fair Ratio

What is 688137's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

688137 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	18x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate 688137's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sichuan Kelun Pharmaceutical

CN¥48.4b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥30.51

2.2%

7.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.59

-2.4%

12.8%

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.91

-1.8%

14.6%